-
The Girl at the End of the World: A Gratitude Day Reflection on the Place that Built Our Science
Latest News
-
Huntington’s disease therapeutics conference 2023 – Day 2
Check out research updates from Day 2 of the 2022 HD Therapeutics Conference #HDTC2023
-
Huntington’s disease therapeutics conference 2023 – Day 1
Check out research updates from Day 1 of the 2022 HD Therapeutics Conference #HDTC2023
-
PROOF-HD study of pridopidine ends with negative result
The phase 3 trial missed its primary endpoint of slowing loss of function in Huntington’s disease
-
Astrocytes: The new star in HD research?
A new article summarizes what the Huntington's disease field has found about a type of brain cell called an astrocyte. These star-shaped cells help keep brain cells healthy and could be leveraged for developing new HD therapeutics.
-
Hunting for balance: how the huntingtin protein compensates in HD
Researchers look at the cause and effect of various forms of the HTT protein. They find both expanded and unexpanded HTT contribute to brain cell communication and the brain has an amazing capacity to compensate for changes related to disease
-
Roche Phase II GENERATION HD2 study underway
Roche released a community letter in early 2023, to share that their Phase II clinical trial to study the huntingtin-lowering drug, tominersen, is now underway. In this article, we summarise the latest news about this huntingtin-lowering drug.
-
Disappointing news from Novartis about branaplam and the VIBRANT-HD trial
Novartis have announced that they are ending development of the drug branaplam in Huntington’s disease. Here, we review this latest news and its impact on the HD community.
-
uniQure gets the green light to resume testing HD gene therapy
Following a 3-month pause in enrollment due to concerns about side effects, uniQure shared the good news that their trial of the HD gene therapy AMT-130 will continue as planned, with new safety measures in place.
-
Update on the PTC Therapeutics PIVOT-HD Trial
Last week, PTC Therapeutics released a statement sharing that recruitment of participants into the US arm of the PIVOT-HD trial has been paused. In this article, we will lay out exactly what is known and what this announcement means.
-
Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials
Two companies developing medicines for Huntington’s disease announced news about their huntingtin-lowering drugs. Let’s talk about the history and the caveats surrounding these hopeful pieces of news.
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
